



PDA Europe gGmbH

Adalbertstraße 9
16548 Glienicke/Berlin
Germany
Tel: +49 (33056) 2377 -10
Fax: +49 (33056) 2377 -77
Georg Roessling, PhD
General Manager
Senior Vice President PDA Europe
<http://europe.pda.org>

OFFICERS

Chair:
Anders Vinther, PhD
Genentech

Chair-Elect:
Harold Baseman
ValSource

Secretary:
Steven Mendivil
Amgen

Treasurer:
Rebecca Devine, PhD
Regulatory Consultant

Immediate Past Chair:
Maik Jornitz
G-Con

President:
Richard M. Johnson

DIRECTORS

Ursula Busse
Novartis

Jette Christensen
Novo Nordisk

Ian Elvins
Lonza AG

John Finkbohner
MedImmune

Gabriele Gori
Novartis Vaccines and Diagnostics

Stephan Rönninger
Amgen

Michael Sadowski
Baxter Healthcare

Junko Sasaki
Dainippon Sumitomo

Sue Schniepp
Allergy Laboratories, Inc.

Lisa Skeens, PhD
Hospira, Inc.

Christopher Smalley, PhD
Merck & Co.

Glenn Wright
Eli Lilly

18 July 2013

European Commission
Health and Consumers Directorate –General, Brussels
sanco-pharmaceuticals-d6@ec.europa.eu

Ref: EU Guidelines for GMP for Medicinal Products; Chapter 6: Quality Control

To the Health and Consumers Directorate-General:

PDA welcomes the opportunity to comment on the proposed changes to this chapter of the EU Guidelines for GMPs. The changes reflect current technologies and controls. The addition of a new section ‘Technical transfer of testing methods’ (6.37 – 6.41) is highly appreciated.

PDA is a non-profit international professional association of more than 10,000 individual member scientists having an interest in the fields of pharmaceutical, biological, and device manufacturing and quality. Our review was completed by an international group of expert volunteers with experience in investigational medicinal products, regulatory affairs and GMP on behalf of our Regulatory Affairs and Quality Advisory Board.

If you have any questions, please contact me.

With very best regards,

Georg Roessling, Ph.D.
Senior VP, PDA Europe
Roessling@pda.org



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

<July 17, 2013>

Submission of comments on EU-GMP Chapter 6

Comments from:

Name of organisation or individual

PDA (The Parenteral Drug Association)

Please note that these comments and the identity of the sender will be published unless a specific justified objection is received.

When completed, this form should be sent to the European Medicines Agency electronically, in Word format (not PDF).



1. General comments

Stakeholder number <i>(To be completed by the Agency)</i>	General comment (if any)	Outcome (if applicable) <i>(To be completed by the Agency)</i>
	Name Comment PDA welcomes the opportunity to comment on the proposed changes. The changes reflect current technologies and controls. The addition of a new section 'Technical transfer of testing methods' (6.37 – 6.41) is highly appreciated.	Decision to Submit/withdraw comment

2. Specific comments on text

Line number(s) of the relevant text <i>(e.g. Lines 20-23)</i>	Stakeholder number <i>(To be completed by the Agency)</i>	Comment and rationale; proposed changes <i>(If changes to the wording are suggested, they should be highlighted using 'track changes')</i>	Outcome <i>(To be completed by the Agency)</i>
Exact Line # (s)	Name (First & Last)	Comment: Proposed change (if any):	Decision to Submit / withdraw comment
6.7		Comment: For the purpose of clarification and with regard to the lack of a clear definition on what an 'out-of-trend' exactly is, PDA recommends substituting 'out-of-trend' by 'evaluation of trends'. Proposed change (if any): A procedure for the investigation of Out Of Specification and anomalous results and Out Of Trend results . the evaluation of trends.	
6.9		Comment: For the purpose of clarification and with regard to the lack of a clear definition on what an 'out-of-trend' exactly is, PDA recommends deleting the wording 'out-of-trend'. Proposed change (if any): Any out of atypical trend or out of specification data should be addressed and subject to investigation.	

Line number(s) of the relevant text <i>(e.g. Lines 20-23)</i>	Stakeholder number <i>(To be completed by the Agency)</i>	Comment and rationale; proposed changes <i>(If changes to the wording are suggested, they should be highlighted using 'track changes')</i>	Outcome <i>(To be completed by the Agency)</i>
6.15		<p>Comment: For the purpose of clarification, PDA recommends to include a reference to ICH Q4B (EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS) Proposed change (if any): add at the end of the sentence: If reference is made to Ph.Eur. alternative <u>harmonised</u> methods <u>appearing in ICH Q4 and</u> described in USP or JP may be used.</p>	
6.21		<p>Comment: PDA recommends using a risk based approach and limiting the requirement to those cases, where the verification of the performance of culture media prior to their use is necessary. Proposed change (if any): suggest to add The performance of culture media should be verified prior to use, if appropriate.</p>	
6.35		<p>Comment: The wording 'negative' trend is open to misinterpretation since a negative trend does not necessarily result in a negative impact on product quality. PDA therefore suggests deleting the wording 'negative'. Proposed change (if any): Suspected out of specification or significant atypical trends should be investigated. Any confirmed out of specification result, or significant negative atypical trend, should be reported to the relevant competent authorities.</p>	

Line number(s) of the relevant text <i>(e.g. Lines 20-23)</i>	Stakeholder number <i>(To be completed by the Agency)</i>	Comment and rationale; proposed changes <i>(If changes to the wording are suggested, they should be highlighted using 'track changes')</i>	Outcome <i>(To be completed by the Agency)</i>
6.37		<p>Comment: PDA agrees that it is appropriate to check the relevance of the original validation. However the level of effort and formality should be left to the company.</p> <p>Proposed change (if any): The original validation of the test method(s) should be reviewed to ensure compliance with current ICH/VICH requirements. If applicable, a gap analysis should be performed and documented to...</p>	
6.38		<p>Comment: For the purpose of the use of harmonised wording in the context of a technology transfer, PDA recommends the adoption of wording as specified in the WHO Guidelines on Transfer of Technology in Pharmaceutical Industry; (WHO guideline http://www.who.int/entity/medicines/areas/quality_safety/quality_assurance/TransferTechnologyPharmaceuticalManufacturingTRS961Annex7.pdf).</p> <p>Proposed change (if any): The transfer of test methodology from one laboratory (transferring laboratory) to another laboratory (receiving laboratory) should be described in an written analytical method transfer protocol. The results of the transfer need to be summarized in an analytical method transfer report.</p>	

Line number(s) of the relevant text <i>(e.g. Lines 20-23)</i>	Stakeholder number <i>(To be completed by the Agency)</i>	Comment and rationale; proposed changes <i>(If changes to the wording are suggested, they should be highlighted using 'track changes')</i>	Outcome <i>(To be completed by the Agency)</i>
6.39		Comment: See detailed comment to 6.38 as regards harmonised wording. The analytical method transfer protocol-should include, but not be limited to, the following parameters: (...)	

Please add more rows if needed.